1. Sweden Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Boule Diagnostics AB

Boule Diagnostics AB

SSTO:BOUL
2.05
SEK
+0.01
(+0.49%)
144.07MMarket Cap
Oct 23Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
10.41
11.53
12.46
14.92
15.6
15.48
18.2
14.6
17.37
19.61
14.71
14.38
12.61
- -
Basic EPS, GAAP
-2.64
1.14
0.58
1.36
1.36
1.5
1.37
-1.75
0.87
0.46
0.64
-7.64
-0.1
- -
Free Cash Flow per Basic Share
-0.65
0.31
0.51
0.53
1.59
-1.52
0.22
1.07
-0.49
-0.64
-0.81
-1.01
-0.11
- -
Dividend per Share
0.09
0.09
0.11
0.11
0.24
0.35
0.39
- -
0.4
0.38
- -
- -
- -
- -
Book Value per Share
4.79
6.39
7.09
8.64
9.55
10.97
12.14
9.82
10.79
11.91
12.23
5.06
4.32
4.5
Tangible Book Value per Share
2.02
2.68
3.27
4.74
5.76
5.18
4.88
2.95
1.98
3.84
2.47
2.5
2.13
2.22
Basic Weighted Avg Shares
27
27
27
27
27
27
27
27
27
28
39
39
39
40
Sales/Revenue/Turnover
277
307
331
397
428
424
499
400
463
548
571
558
490
- -
Operating Margin (%)
-29.7
8.59
7.66
12.64
13.25
12.38
13.99
-1.11
7.74
6.11
7.61
-48.09
9.91
- -
Depreciation Expense
4
4
5
8
11
8
21
22
21
27
25
23
19
- -
Net Income, GAAP
-70
30
15
36
37
41
38
-48
23
13
25
-297
-4
- -
Effective Tax Rate (%)
- -
- -
24.75
23.48
30.19
25.04
25.76
- -
19.1
38.95
17.02
- -
163.49
- -
Profit Margin (%)
-25.33
9.87
4.63
9.08
8.7
9.67
7.53
-11.98
5.02
2.32
4.37
-53.11
-0.77
- -
Working Capital
42
36
54
107
146
51
57
44
31
137
77
-8
18
15
LT Debt
8
9
12
27
27
12
61
42
51
85
69
53
90
85
Total Equity
127
170
189
230
262
301
333
269
296
463
475
196
168
175
Return on Invested Capital (%)
- -
- -
6.75
13.04
12.02
11.24
11.72
- -
6.74
3.14
4.95
- -
-3.28
- -
Return on Capital (%)
- -
- -
6.84
13.39
12.19
11.79
9.45
- -
6.54
3.39
5.31
- -
-3.53
- -
Return on Common Equity (%)
-42.87
20.35
8.56
17.23
15.15
14.59
11.85
-15.93
8.24
3.36
5.33
-88.34
-2.06
- -

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
134
134
143
LT Borrowings
59
51
49
LT Finance Leases
31
37
35
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
39
39
39
Market Capitalization
191
153
144

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
225
218
232
Cash, Cash Equivalents & STI
20
19
20
Accounts Receivable, Net
129
116
119
Inventories
59
64
66
Total Current Liabilities
207
205
217
Payables & Accruals
- -
- -
- -
ST Debt
134
134
143
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.79%
-0.88%
-14.63%
Free Cash Flow
19.77%
-19.33%
-89.42%
Net Income, GAAP
-157.17%
-296.75%
-98.73%
Sales/Revenue/Turnover
4.83%
4.73%
-12.31%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
148
137
131
143
558
2025
113
129
- -
120
490
2026
102
112
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.25
-0.04
-5.9
-1.95
-7.64
2025
-0.27
-0.15
- -
0.04
-0.1
2026
-0.38
-0.04
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Johan Folkunger
Full Time Employees
200
Sector
Health technology
Industry
Medical specialties
Address
Domnarvsgatan 4 Spanga AB Sweden 163 53
IPO Date
May 24, 2011
Website
boule.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Boule Diagnostics AB (publ) develops, manufactures and markets hematology analyzers, clinical chemistry analyzers and associated reagents, controls and calibrators for decentralized blood diagnostics in human and veterinary markets; offers customized private-label and OEM products through its US subsidiary Clinical Diagnostic Solutions for hematology, flow cytometry, chemistry and coagulation systems; and provides complete diagnostic systems including brands such as Swelab Alfa Plus, Medonic M-series (M32, M51), Quintus 5-part, Exigo veterinary series and H50V veterinary hematology analyzer. The company, founded in 1992 and headquartered in Spånga, Sweden, operates subsidiaries in the USA and Russia, sells through over 200 distributors in more than 100 countries targeting small and medium-sized hospitals, clinics, laboratories and outpatient care settings, and lists its shares on Nasdaq Stockholm since 2010. Recent developments include a new brand identity and logo launch in 2025, restructuring into Diagnostics and OEM segments in 2025 for enhanced strategic clarity, closure of the BM-900/BM950 development project in early 2025 due to technical issues, an exclusive US distribution agreement with Vital Scientific for clinical chemistry solutions earlier in 2025, a technology partner supply agreement for a new veterinary instrument launching in 2026, strong 16% instrument sales growth in Q3 2025 driven by 5-part technology demand, and ongoing site consolidation in Spånga alongside cost reductions achieving positive operating cash flow.